Investing.comCodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:00:38时区推断·⟳ 抓取 19:05:01·⚡ 决策 08-04 23:03:12 +3h58m·84.0 天前
Rhythm公布RM-718治疗获得性下丘脑性肥胖2期初步积极数据，但本条为已处理重复催化
RM-718在11例获得性下丘脑性肥胖患者的2期初步数据中，完成16周治疗的7例平均BMI较基线下降11.6%，方向上利好Rhythm Pharmaceuticals（RYTM.US）的肥胖管线预期。
📄 原文Investing.com↗ 原文
Rhythm Pharmaceuticals reports RM-718 trial results in obesity
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets BOSTON - Rhythm Pharmaceuticals Inc. (NASDAQ:R…
不做 Rhythm Pharmaceuticals（RYTM.US）
不做：已处理消息库命中同一具体催化，2026-08-04 11:01 UTC wire与11:04 IR页面已处理RM-718获得性下丘脑性肥胖2期初步积极数据，12:55 Reuters也已被标记为重复转述；本条Investing.com没有新增事实。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 high · price-in 风险 high ↗
关键理由
- RM-718在11例获得性下丘脑性肥胖患者的2期初步数据中，完成16周治疗的7例平均BMI较基线下降11.6%，方向上利好Rhythm Pharmaceuticals（RYTM.US）的肥胖管线预期。
- 但近12小时已命中同一具体催化的wire、IR页面、Reuters和系统决策记录，本条Investing.com转述没有新增疗效、安全性或商业化事实。
主要风险
- 本条为重复转述，重复推送会造成同一RM-718初步数据催化的二次打扰；若后续出现正式完整数据、监管沟通或商业化指引变化，应由新事件重新研判。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,796 字
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
BOSTON - Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) announced Tuesday preliminary results from its Phase 2 trial of RM-718, an investigational once-weekly MC4R agonist, in patients with acquired hypothalamic obesity.
The trial enrolled 11 patients with acquired hypothalamic obesity. Seven patients who completed 16 weeks of treatment showed a mean BMI reduction of 11.6% from baseline, according to a company press release statement.
The company compared these results to a 10.1% mean BMI reduction with bivamelagon at 14 weeks in seven patients and a 10.1% BMI reduction with setmelanotide at 16 weeks in 64 patients from Phase 2 and 3 trials.
Two mild cases of hyperpigmentation were reported at the injection site, with no generalized hyperpigmentation observed. The most common adverse events included injection site reactions, nausea, and vomiting.
As of July 16, 2026, eight patients remained on active treatment, including two who had not yet reached 16 weeks on therapy. Two participants discontinued treatment due to adverse events: injection site induration and nausea. One patient withdrew from the extension portion of the trial.
RM-718 is designed to be highly selective and MC1R-sparing to reduce the frequency and severity of hyperpigmentation.
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company. Its lead product, IMCIVREE (setmelanotide), is approved by the FDA for treating hyperphagia and severe obesity in specific patient populations.
The company scheduled a conference call for today at 8:00 a.m. ET to discuss second quarter 2026 financial results and business updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOSTON - Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) announced Tuesday preliminary results from its Phase 2 trial of RM-718, an investigational once-weekly MC4R agonist, in patients with acquired hypothalamic obesity.
The trial enrolled 11 patients with acquired hypothalamic obesity. Seven patients who completed 16 weeks of treatment showed a mean BMI reduction of 11.6% from baseline, according to a company press release statement.
The company compared these results to a 10.1% mean BMI reduction with bivamelagon at 14 weeks in seven patients and a 10.1% BMI reduction with setmelanotide at 16 weeks in 64 patients from Phase 2 and 3 trials.
Two mild cases of hyperpigmentation were reported at the injection site, with no generalized hyperpigmentation observed. The most common adverse events included injection site reactions, nausea, and vomiting.
As of July 16, 2026, eight patients remained on active treatment, including two who had not yet reached 16 weeks on therapy. Two participants discontinued treatment due to adverse events: injection site induration and nausea. One patient withdrew from the extension portion of the trial.
RM-718 is designed to be highly selective and MC1R-sparing to reduce the frequency and severity of hyperpigmentation.
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company. Its lead product, IMCIVREE (setmelanotide), is approved by the FDA for treating hyperphagia and severe obesity in specific patient populations.
The company scheduled a conference call for today at 8:00 a.m. ET to discuss second quarter 2026 financial results and business updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。